Abstract
Introduction Digital technologies have the potential to support clinical pathways. This study aims to evaluate the impact of using an artificial intelligence-based conversational assistant known as Dora in the cataract pathway. Dora conducts clinical conversations with patients over a telephone call both before and after cataract surgery. Through automation of routine activity, the aim is to increase efficiency of the cataract pathway and the capacity of organisations.
Method and Analysis We will use a mixed-methods cohort-based approach across all sites using Dora in South East England. The study has 3 key objectives, to: 1) Report site-specific variation on the implementation and impact of using Dora 2) assess the impact on the triple bottom line (financial, social and environmental performance) through implementation of Dora 3) understand the real-world patient outcomes of using Dora in clinical pathways. The Dora platform prospectively records symptom and outcome information from each call. We will retrospectively collect data from the hospital record and also collect qualitative data regarding the ease of implementation and patient acceptability of the technology.
Ethics and dissemination This will be registered as a service evaluation at each of the participating clinical sites. Research ethics is not needed as per Health Research Authority guidelines. Site-specific reports will be provided to each participant site as well as an overall report to be disseminated through NHS-England. Results will be published in a formal project report endorsed by stakeholders, and in peer-reviewed scientific reports.
Strengths
- This is the largest study on the use of an AI based natural language clinical assistant across multiple different hospital sites, with varied geographical locations, demographics and baseline clinical pathways.
- This is a large-scale evaluation with input from multiple independent clinicians, patients, evaluators, economists and strategists.
- Standardised data collection from autonomous clinical assistant
Limitations
- Retrospective collection of hospital level follow up data
Competing Interest Statement
AH, EL, SK, LS and NP are all employees of Ufonia Limited, a voice AI company. AH is also employed by Royal Berkshire Hospital and Oxford University Hospitals NHS Foundation Trust as a trainee Ophthalmologist. Her work for Ufonia is declared on the Trust register of interests.
Funding Statement
The Small Business Research Initiative (SBRI) is funding the delivery of Dora calls in the Berkshire, Oxfordshire and Buckinghamshire and Frimley Integration Care Systems (ICSs) via a Reset and Recovery Grant. NHS England have commissioned the use of Dora for cataract surgery conversations for up to six sites in South East England (excluding calls funded by the SBRI grant). The Medical Protection Society Foundation has awarded a grant to fund the wellbeing work package.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Buckinghamshire Healthcare NHS Trust Project Classification Group has determined that the project meets a definition of Service Review/Quality Improvement. Project Classification Group Reference: PCG138.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.